The government has now announced an investigation into the workings of India's main drug regulator, days after the panel's report. Three experts have been appointed to "look at the scientific basis of approving new drugs without clinical trials" and recommend ways of improving the way the Central Drugs Standard Control Organisation (CDSO) works. One report says that global drug makers could also face new US scrutiny following this damning 78-page report.